FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
The use of dichloroacetate (DCA) was shown to have therapeutic effects in the treatment of Leigh’s syndrome. The chemical activates pyruvate dehydrogenase and thus causes a reduction in blood lactate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results